Search clinical trials for: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm

Total 16 results

University of Leeds
Takeda; Cancer Research UK; Celgene

Recruiting

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)

Multiple Myeloma

United Kingdom
Universitätsklinikum Hamburg-Eppendorf
Gemeinsamer Bundesausschuss (G-BA); Staburo GmbH

Recruiting

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM)

Multiple Myeloma

Germany
University of Pennsylvania
Active Biotech AB

Recruiting

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Multiple Myeloma

United States
University of Leeds
Merck Sharp & Dohme LLC; Celgene; Amgen

Unknown

Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients (Myeloma XI)

Multiple Myeloma

United Kingdom
University of Leeds
Takeda; Cancer Research UK

Recruiting

The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

Multiple Myeloma

United Kingdom
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Institute of Hematology & Blood Diseases Hospital

Unknown

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Multiple Myeloma | Plasma Cell Leukemia | Extramedullary Plasmacytoma | Loss of Chromosome 17p | t(14;16) | t(4;14) | Complex Karyotype | T(14;20) | 1Q21 Amplification

China
Alliance Foundation Trials, LLC.
Takeda; Janssen Scientific Affairs, LLC; Celgene Corporation

Active, not recruiting

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Myeloma, Multiple

United States
University of Alabama at Birmingham
Janssen Scientific Affairs, LLC

Recruiting

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

Multiple Myeloma

United States
Sun Yat-sen University

Recruiting

Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma

Lymphoma, Lymphoblastic

China
Ain Shams University

Unknown

Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

Egypt
University of Arkansas
Amgen

Terminated

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Tufts Medical Center; Lahey Clinic

Completed

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Multiple Myeloma

United States
Nanfang Hospital of Southern Medical University

Unknown

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Leukemia, Acute | Leukemia, Lymphoblastic | Leukemia, T Cell

China
Nanfang Hospital of Southern Medical University

Unknown

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Leukemia | Lymphoblastic Lymphoma | Lymphoblastic Leukemia | Leukemia, Acute | Adult Lymphoblastic Lymphoma | Leukemia, Lymphoblastic | Leukemia, T Cell | Adult Acute Lymphoblastic Leukemia

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

Leukemia

United States, Canada, Netherlands, Puerto Rico, Switzerland

Search clinical trials for: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations